XCF Global enters $7.5 million convertible note agreement with EEME Energy
PLEASANTON, Calif. - 10x Genomics Inc. (NASDAQ: TXG), a $1.1 billion market cap company known for its work in single cell and spatial biology, has reached a settlement with Bruker Corporation, ending all ongoing patent litigations globally. According to InvestingPro data, the company maintains strong financial health with a robust 68% gross margin and holds more cash than debt on its balance sheet. The agreement involves Bruker paying 10x Genomics $68 million in installments from the third quarter of 2025 through the second quarter of 2026, along with ongoing royalties on Bruker’s spatial biology product sales. The news has contributed to the stock’s recent positive momentum, with InvestingPro showing a 16% return over the past week.
This settlement concludes a series of legal proceedings between the two companies in various jurisdictions, including the United States, Germany, and the European Unified Patent Court. The terms of the settlement also encompass global patent cross-licenses and the withdrawal of all legal actions.
Serge Saxonov, CEO of 10x Genomics, emphasized the importance of protecting intellectual property for the advancement of science and human health. Eric Whitaker, Chief Legal Officer at 10x, underscored the settlement as a testament to the value of the company’s intellectual property portfolio and its significance in the field of spatial biology.
The settlement is expected to allow 10x Genomics to continue investing in innovation and supporting its mission in the life sciences sector. The company, which provides integrated solutions including instruments, consumables, and software, has been instrumental in scientific breakthroughs across various fields such as oncology and immunology.
The financial impact of the settlement and license agreements with Bruker is included in forward-looking statements within the press release, which are subject to risks and uncertainties. These could cause actual outcomes to differ from current expectations.
The information regarding the settlement is based on a press release statement from 10x Genomics.
In other recent news, 10X Genomics reported its first-quarter 2025 financial results, surpassing both Canaccord’s projections and the FactSet consensus. The company achieved this milestone even without the one-time revenue boost from a patent litigation settlement with Vizgen. This success was attributed to solid growth in consumables revenue, including Chromium and Spatial products. However, 10X Genomics has chosen to withdraw its revenue guidance for 2025 due to concerns about the challenging macroeconomic environment. For the second quarter of 2025, the company expects revenue to remain consistent with the first quarter, excluding the settlement benefit, and anticipates potential growth as macroeconomic conditions improve.
Additionally, 10X Genomics secured a worldwide permanent injunction against Parse Biosciences, prohibiting them from manufacturing or selling certain products that infringed on 10X’s patents. This legal victory further strengthens 10X Genomics’ patent portfolio, though litigation against Parse’s gene expression products is ongoing. Canaccord Genuity adjusted its price target for 10X Genomics shares, lowering it to $15.00 from $18.00, while maintaining a Buy rating, reflecting a cautious outlook amid macroeconomic uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.